Added to YB: 2024-06-18
Pitch date: 2024-06-14
OVID [bullish]
Ovid Therapeutics Inc.
+49.09%
current return
Author Info
No bio for this author
Company Info
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States.
Market Cap
$20.0M
Pitch Price
$1.10
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.33
P/E
-0.77
EV/Sales
-32.34
Sector
Biotechnology
Category
special_situation
Ovid Therapeutics
OVID: Takeda partnership for soticlestat rare childhood epilepsy treatment. $660M milestones + 20% royalties, no further capital needed. Leadership has skin in game. NPV of royalties at 15% discount rate: $1B (5x market cap, 10x EV) if Ph3 succeeds by mid-2024. 50% downside if fails.
Read full article (2 min)